Synendos Therapeutics AG

Synendos is a Phase 2 clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders. We utilise the modulation of a new drug target identified following a decade of research at UniBern into the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. There is a urgent unmet need for effective and better tolerated therapies to treat these disorders.

Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first in class molecules that modulate the ECS through a self-limiting mode of action that avoids over stimulation and enables restoration of normal brain function with improved patient tolerability. As a result, the SERI drug class has the potential for expansion across multiple indications with the potential to deliver meaningful benefits to patients.

We are currently fundraising a Series B round to finance the next stages of clinical development.